Harnessing genomic knowledge to address antimicrobial resistance
We believe that every TB patient has a right to rapid and complete drug susceptibility testing.
Ensuring that the drug regimen is optimized for each patient maximizes treatment efficacy and provides
the best chance for individual cure.
ReSeqTB is a global data sharing platform and knowledge base with a vision to provide clinically
relevant antimicrobial resistance interpretive algorithms using next generation sequencing
technologies to enable rapid and effective personalized drug treatment.
Our goal is to provide stakeholders standardized reports to facilitate rapid and better-informed
patient management through personalized medicine.
Who we are
The ReSeqTB global initiative is led by a collaborative partnership which includes the Bill & Melinda Gates Foundation
(BMGF), Critical Path Institute (C-Path), Foundation for Innovative New Diagnostics (FIND),
and the World Health Organization (WHO).
This resource is made possible by the contribution of the research community.
We are indebted to clinicians, nurses, researchers and tuberculosis patients who have allowed their
data to be used in compiling this information in hopes to facilitate faster and more accurate
diagnosis of drug resistance.